美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Obsidian Therapeutics Inc

18.30

+0.50002.81%

成交量：33.59萬

成交額：610.85萬

市值：11.30億

市盈率：-4.31

高：19.00

開：18.39

低：17.84

收：17.80

52周最高：49.97

52周最低：14.57

股本：6,172.72萬

流通股本：5,946.21萬

量比：1.12

換手率：0.56%

股息：- -

股息率：- -

每股收益(TTM):-4.2465

每股收益(LYR):-2,056.1834

淨資產收益率：--

總資產收益率：--

市淨率：-3.77

市盈率(LYR):-0.01

資料載入中...

總覽公司新聞資訊公告

Obsidian Therapeutics提交招股説明書，涉及最多29,164,045股普通股轉售

Obsidian Therapeutics宣佈：晚期黑色素瘤新藥Amsoki-Cel (Obx-115) 關鍵註冊隊列首例患者成功入組

美國研究綜述-Ametek、Ball Corp、麥當勞

美國研究綜述-Ametek、Ball Corp、麥當勞

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/hant/stock/OBX/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"OBX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OBX\",,,,,undefined,":{"symbol":"OBX","market":"US","secType":"STK","nameCN":"Obsidian Therapeutics Inc","latestPrice":18.3,"timestamp":1789410857050,"preClose":17.8,"halted":0,"volume":335916,"delay":0,"changeRate":0.028089887640449437,"floatShares":59462058,"shares":61727211,"eps":-4.246465,"marketStatus":"交易中","change":0.5,"latestTime":"09-14 14:34:31 EDT","open":18.39,"high":18.998,"low":17.84,"amount":6108475.923144,"amplitude":0.065056,"askPrice":18.5,"askSize":80,"bidPrice":18.2,"bidSize":120,"shortable":3,"etf":0,"ttmEps":-4.246465,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1789416000000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":17.8,"postHourTrading":{"tag":"盘后","latestPrice":17.8,"preClose":17.8,"latestTime":"19:30 EDT","volume":11,"amount":195.8,"timestamp":1789169406852,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.11929},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OBX\",,,,,undefined,":{"symbol":"OBX","floatShares":59462058,"roa":"--","roe":"--","lyrEps":-2056.183449,"volumeRatio":1.11929,"shares":61727211,"dividePrice":0,"high":18.998,"amplitude":0.065056,"preClose":17.8,"low":17.84,"week52Low":14.57,"pbRate":"-3.77","week52High":49.9699,"institutionHeld":0,"latestPrice":18.3,"committee":0.2,"eps":-4.246465,"divideRate":0,"volume":335916,"delay":0,"ttmEps":-4.246465,"open":18.39,"prevYearClose":49.9699,"prevWeekClose":17.8,"prevMonthClose":17.51,"prevQuarterClose":49.9699,"fiveDayClose":16.82,"twentyDayClose":17.77},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OBX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-04","symbol":"OBX","defaultRemindTime":1785850200000,"type":"split","dateTimestamp":1785816000000,"forFactor":10000,"toFactor":7019,"ratio":1.4247043738424277}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OBX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"OBX\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/OBX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"OBX","date":"2026-09-11","current":-4.309467,"percent":0.26087,"low":-15.919767,"twenty":-12.259905,"median":-9.14022,"eighty":-8.254627,"high":-7.414063,"avg":-10.25711,"sd":2.277254,"marketCap":1060022552},"quantilePoints":[{"date":"2026-08-14","current":-8.605771,"twenty":-15.155618,"median":-12.735814,"eighty":-11.727865,"marketCap":819734144},{"date":"2026-08-21","current":-9.183431,"twenty":-13.181567,"median":-9.14022,"eighty":-8.501155,"marketCap":874758582},{"date":"2026-08-28","current":-7.750652,"twenty":-12.553874,"median":-9.051525,"eighty":-8.311938,"marketCap":738280646},{"date":"2026-09-04","current":-11.204373,"twenty":-11.465176,"median":-9.062896,"eighty":-8.061315,"marketCap":1055698450},{"date":"2026-09-11","current":-11.250266,"twenty":-12.259905,"median":-9.14022,"eighty":-8.254627,"marketCap":1060022552}],"updateTime":1789410871353},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"OBX\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1180960798","title":"Obsidian Therapeutics提交招股説明書，涉及最多29,164,045股普通股轉售","url":"https://stock-news.laohu8.com/highlight/detail?id=1180960798","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180960798?lang=zh_tw&edition=fundamental","pubTime":"2026-08-29 05:13","pubTimestamp":1787951593,"startTime":"0","endTime":"0","summary":"Obsidian Therapeutics Inc已向美国证券交易委员会提交了一份招股说明书，内容涉及出售股东转售最多29,164,045股普通股。此次提交的招股说明书并未涉及公司自身的资金募集行为，而是旨在为股东提供一个合规的转售平台。值得关注的是，Obsidian Therapeutics专注于细胞疗法的开发，其核心研发管线正处於临床前及早期临床阶段。此类公司的股价对融资及股东活动尤为敏感，本次提交的招股书亦将成为投资者近期评估该公司股票供需关系的关键参考。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OBX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160444967","title":"Obsidian Therapeutics宣佈：晚期黑色素瘤新藥Amsoki-Cel (Obx-115) 關鍵註冊隊列首例患者成功入組","url":"https://stock-news.laohu8.com/highlight/detail?id=1160444967","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160444967?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 19:06","pubTimestamp":1785927982,"startTime":"0","endTime":"0","summary":"Obsidian Therapeutics公司今日重磅宣布，其针对晚期黑色素瘤的细胞疗法——Amsoki-Cel（原名Obx-115），在1/2期Agni-01研究的注册导向队列中，已成功完成首例患者入组。这一里程碑事件，标志着该创新疗法正式迈入关键性临床开发阶段，为全球黑色素瘤患者带来了全新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657519496","title":"美國研究綜述-Ametek、Ball Corp、麥當勞","url":"https://stock-news.laohu8.com/highlight/detail?id=2657519496","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657519496?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 15:57","pubTimestamp":1785916639,"startTime":"0","endTime":"0","summary":"美国研究综述-Ametek、Ball Corp、麦当劳路透8月5日-周三，华尔街证券分析师下调了多家在美国上市公司的评级和目标股价，其中包括阿美特克、鲍尔公司和麦当劳。要点* 阿美特克AME.N：加拿大皇家银行将目标价从260美元上调至291美元* 博尔公司BALL.N：摩根大通将评级从“增持”下调至“中性”* 麦当劳MCD.N：摩根大通将目标价从305美元下调至280美元以下是路透周三报道的针对美国公司的研究报告摘要。股票按字母顺序排列。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL4S4420OI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBIN","QLYS","BALL","GILD","NPO","MRK","CINF","PINS","W","MCD","KTOS","SYY","IT","HSIC","OPLN","TOST","TVTX","YETI","EMR","SPCX","AME","BR","AMGN","AMD","PRCT","BRKR","PLTR","JXN","ZBRA","ALAB","LSCC","XMTR","BKNG","BL","CMI","MKL","OBX","BDX","HNGE","PPLI","LMAT","CAT","ANET","HLNE","BBY","ARWR","PCTY","TPG","WAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657499519","title":"美國研究綜述-Ametek、Ball Corp、麥當勞","url":"https://stock-news.laohu8.com/highlight/detail?id=2657499519","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657499519?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 15:57","pubTimestamp":1785916639,"startTime":"0","endTime":"0","summary":"美国研究综述-Ametek、Ball Corp、麦当劳路透8月5日-周三，华尔街证券分析师下调了多家在美国上市公司的评级和目标股价，其中包括阿美特克、鲍尔公司和麦当劳。要点* 阿美特克AME.N：加拿大皇家银行将目标价从260美元上调至291美元* 博尔公司BALL.N：摩根大通将评级从“增持”下调至“中性”* 麦当劳MCD.N：摩根大通将目标价从305美元下调至280美元以下是路透周三报导的针对美国公司的研究报告摘要。股票按字母顺序排列。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL4T4420OI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HNGE","LMAT","BBY","ALAB","GILD","AMGN","JXN","CMI","FBIN","AMD","ZBRA","HLNE","BALL","PCTY","OBX","PINS","CAT","QLYS","BL","TVTX","MKL","PPLI","HSIC","MCD","OPLN","LSCC","KTOS","MRK","EMR","TOST","ANET","PRCT","SPCX","BKNG","NPO","WAT","SYY","PLTR","BDX","TPG","CINF","AME","W","BR","BRKR","IT","YETI","ARWR"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":4,"code":"91000000","status":"200"}]}}